What is Rnatives?
Rnatives is a biotechnology firm focused on developing RNA activation (saRNA) therapeutics. The company's innovative platform is built upon novel nuclear microRNA biology, enabling the modulation of gene expression. This approach targets the development of novel treatments for complex conditions such as cardiovascular and neurological diseases, positioning Rnatives at the forefront of genetic medicine innovation.
How much funding has Rnatives raised?
Rnatives has raised a total of $3.2M across 1 funding round:
Seed
$3.2M
Seed (2025): $3.2M with participation from Business Finland, Force 10 Partners, and Nordic Science Investments Oy
Key Investors in Rnatives
Business Finland
Business Finland is a Finnish public organization that provides innovation funding and internationalization services, supporting Finnish companies in their growth and global reach.
Force 10 Partners
Force 10 Partners is an advisory firm specializing in corporate restructuring and special situations, offering investment banking and fiduciary services to companies facing complex financial challenges.
Nordic Science Investments Oy
Nordic Science Investments Oy is a venture capital firm dedicated to transforming scientific discoveries into startups, with a focus on deeptech, healthtech, and life sciences in the New Nordics region.
What's next for Rnatives?
The substantial enterprise-level funding, particularly the recent strategic investment, indicates Rnatives is poised for significant scaling and clinical advancement. This capital infusion will likely accelerate its research and development pipeline, facilitate broader clinical trials, and potentially support market entry strategies for its saRNA therapeutics. The company's focus on addressing critical unmet needs in cardiovascular and neurological health suggests a strategic expansion into key therapeutic areas.
See full Rnatives company page
